TY - JOUR
T1 - 2nd ESMO Consensus Conference in Lung Cancer
T2 - Locally advanced stage III non-small-cell lung cancer
AU - Panel Members
AU - Eberhardt, Wilfried E.E.
AU - De Ruysscher, Dirk
AU - Weder, Walter
AU - Le Péchoux, Cecile
AU - De Leyn, Paul
AU - Hoffmann, H.
AU - Westeel, Virginie
AU - Stahel, Rolf
AU - Felip, Enriqueta
AU - Peters, Solange
AU - Kerr, Keith
AU - Besse, Benjamin
AU - Vansteenkiste, Johan
AU - Edelman, Martin
AU - Mok, Tony
AU - O'Byrne, Ken
AU - Novello, Silvia
AU - Bubendorf, Lukas
AU - Marchetti, Antonio
AU - Baas, Paul
AU - Reck, Martin
AU - Syrigos, Konstantinos
AU - Paz-Ares, Luis
AU - Smit, Egbert F.
AU - Meldgaard, Peter
AU - Adjei, Alex
AU - Nicolson, Marianne
AU - Crinò, Lucio
AU - Van Schil, Paul
AU - Senan, Suresh
AU - Faivre-Finn, Corinne
AU - Rocco, Gaetano
AU - Veronesi, Giulia
AU - Douillard, Jean Yves
AU - Lim, Eric
AU - Dooms, Christophe
PY - 2015/1/1
Y1 - 2015/1/1
N2 - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.
AB - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.
KW - ESMO
KW - Locally advanced
KW - Non-small-cell lung cancer
KW - Recommendations
KW - Stage III
UR - http://www.scopus.com/inward/record.url?scp=84941599354&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/annonc/mdv187
DO - https://doi.org/10.1093/annonc/mdv187
M3 - Article
C2 - 25897013
SN - 0923-7534
VL - 26
SP - 1573
EP - 1588
JO - Annals of Oncology
JF - Annals of Oncology
IS - 8
ER -